In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor. What is your thought on this?

Should PFS outcomes drive treatment decisions in aBC when statistical significant improvement in OS is shown?

Kisqali Channel

00:07:05

Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?

Dr. Tanja Fehm is discussing on "Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?"

Kisqali Channel

00:02:25

Does the use of Kisqali delay time to chemotherapy (in M3 trial)? And which numbers should we remember?

Professor Janice Walshe is discussing "Does the use of Kisqali delays time to chemotherapy (in M3 trial) ? And which numbers should we remember?"

Kisqali Channel

00:01:42

Can you describe more into depth the hormone resistant patient population included in M3 trial?

Professor Mario Campone is describing more into depth the hormone resistant patient population included in M3 trial.

Kisqali Channel

00:03:54

How clinical relevance is assessed in randomized clinical trials?

Kisqali Channel

00:05:42

Is it easy to show overall survival in 1L HR+ HER2 – ABC?

Dr. Mattea Reinisch is talking on "Is it easy to show overall survival in 1L HR+ HER2 – ABC?"

Kisqali Channel

00:03:14